[ad_1] NEW YORK, Dec. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, […]

[ad_1] NEW YORK, Dec. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. (“Viking” or the “Company”) (NASDAQ: VKTX). Such investors are advised to contact Danielle Peyton […]

[ad_1] NEW YORK, Dec. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of e.l.f. Beauty, Inc. (“e.l.f. Beauty” or the “Company”) (NYSE: ELF).  Such investors are advised to contact Danielle […]

[ad_1] NEW YORK, Dec. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. (“Neurogene” or the “Company”) (NASDAQ: NGNE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  […]

[ad_1] NEW YORK, Dec. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ: SYRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, […]